Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Hope you had a delightful weekend. Up today: an exclusive look at the scientific mix-up behind the approval of preterm birth drug Makena. We hear from a mother of a son with Duchenne muscular dystrophy who wants to ensure the FDA’s accelerated approval pathway stays strong, and more.
The mix-up behind a controversial drug for preterm birth
Last year, the FDA withdrew its approval of Makena, the progesterone-based drug meant to prevent preterm birth, when follow-on studies failed to prove its efficacy. A little-known facet to the Makena story is largely untold, as STAT’s Annalisa Merelli writes, describing a key error in the widely cited study that underpinned the drug’s initial approval.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.statnews.com/2024/04/22/biotech-news-makena-17p-antibiotics-duchenne-novo-nordisk/?utm_campaign=rss